.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Fuji
McKesson
US Department of Justice
Farmers Insurance
Chinese Patent Office
US Army
Teva
Moodys
Merck

Generated: September 23, 2017

DrugPatentWatch Database Preview

Tolvaptan - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for tolvaptan and what is the scope of tolvaptan freedom to operate?

Tolvaptan
is the generic ingredient in one branded drug marketed by Otsuka America Pharm and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Tolvaptan has sixty-four patent family members in nineteen countries.

There are six drug master file entries for tolvaptan. One supplier is listed for this compound.

Summary for Generic Name: tolvaptan

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list6
Suppliers / Packagers: see list1
Bulk Api Vendors: see list55
Clinical Trials: see list72
Patent Applications: see list658
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:tolvaptan at DailyMed

Pharmacology for Ingredient: tolvaptan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-001May 19, 2009RXYesNo► Subscribe► Subscribe ► Subscribe
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-003May 19, 2009DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-003May 19, 2009DISCNYesNo► Subscribe► Subscribe ► Subscribe
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-001May 19, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-002May 19, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-002May 19, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: tolvaptan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-001May 19, 2009► Subscribe► Subscribe
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-003May 19, 2009► Subscribe► Subscribe
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275-002May 19, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: tolvaptan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,273,735Process for preparing benzazepine compounds or salts thereof► Subscribe
5,985,869 Benzoheterocyclic compounds► Subscribe
5,559,230 Benzoheterocyclic compounds► Subscribe
5,258,510 United States Patent: 5258510   ( 1► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tolvaptan

Country Document Number Estimated Expiration
South Korea0167349► Subscribe
Portugal2251319► Subscribe
JapanH0776214► Subscribe
Australia7291791► Subscribe
China101967107► Subscribe
Portugal1919874► Subscribe
Germany602006019882► Subscribe
World Intellectual Property Organization (WIPO)9105549► Subscribe
Hong Kong1148999► Subscribe
Hong Kong1144932► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TOLVAPTAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/037United Kingdom► SubscribePRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
00408Netherlands► SubscribePRODUCT NAME: TOLVAPTAN, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/09/539/001-004 20090803
2009 00031Denmark► Subscribe
C0049France► SubscribePRODUCT NAME: TOLVAPTAN, EVENTUELLEMENT SOUS FORME DE SEL; REGISTRATION NO/DATE: EU/1/09/539/001 20090803
0408Netherlands► Subscribe300408, 20101018, EXPIRES: 20151017
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Merck
QuintilesIMS
Cerilliant
Teva
Farmers Insurance
Medtronic
Julphar
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot